Patrick Whelan, MD
Urology · Suffolk, VANPI 1851704639
Payments from drug & device makers
What this record shows
This record is dominated by other: $75,333 of the $113,857 with a category attached, or 66.2%. Angiodynamics, Inc. accounts for 66.2% of it on its own, with 41 other manufacturers making up the rest. 2025 is the largest year on record at $61,016, 2.4 times the $25,429 reported in 2019. Among urology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $527.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$75K
- Boston Scientific$25K
- Ambu Inc.$8K
- AbbVie$719
- Johnson & Johnson$719
- Pfizer$389
- plus $3K from 36 others
What the payments were for
- Consulting fees$7,9157%
- Grants$25,00022%
- Food & beverage$5,4455%
- Education$1640%
- Other$75,33366%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 2 | $75,333 |
| Boston Scientific | 6 | $25,429 |
| Ambu Inc. | 10 | $8,139 |
| AbbVie(2 entities) | 33 | $719 |
| Johnson & Johnson | 21 | $719 |
| Pfizer | 20 | $389 |
| Bayer | 12 | $271 |
| Sumitomo Pharma America, Inc. | 10 | $237 |
| Teleflex LLC | 4 | $216 |
| Astellas Pharma US Inc | 10 | $215 |
| Progenics Pharmaceuticals, Inc. | 6 | $212 |
| Medtronic | 5 | $191 |
| Abbott | 1 | $148 |
| Merck | 6 | $135 |
| Antares Pharma, Inc. | 6 | $111 |
| Tolmar, Inc. | 5 | $110 |
| Endo Pharmaceuticals Inc. | 6 | $109 |
| Myovant Sciences Inc. | 5 | $104 |
| Conmed Corporation | 1 | $104 |
| Myriad Genetic Laboratories, Inc. | 6 | $102 |
| Accord Healthcare, Inc. | 5 | $93 |
| Urogen Pharma, Inc. | 4 | $89 |
| Tempus AI, Inc | 4 | $89 |
| Intuitive Surgical | 1 | $83 |
| Novo Nordisk | 3 | $62 |
| Amgen | 3 | $52 |
| Blue Earth Diagnostics | 2 | $47 |
| Novartis | 2 | $44 |
| Olympus America Inc. | 2 | $42 |
| Coloplast | 2 | $31 |
| Urovant Sciences Inc | 2 | $28 |
| Dendreon Pharmaceuticals LLC | 1 | $24 |
| Axonics, Inc. | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Immunitybio, Inc. | 1 | $19 |
| Endo USA, Inc. | 1 | $19 |
| Halozyme Inc | 1 | $19 |
| Hollister Incorporated | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $17 |
| 180 Medical, Inc. | 1 | $17 |
| Innovation Technologies Inc | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$75,333
- GENERAL KIDNEY STONE DISEASE$25,000
- GENERAL - THERAPIES$272
- AVEIR$148
- UroLift$139
- Erleada$119
- PYLARIFY$114
- AIRSEAL$104
How this compares
$113,857 in reported general payments places this provider in the 95th percentile of 300 urology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 54 | $55,780 |
| GemtesaVibegron | 19 | $26,039 |
| Tamsulosin Hcl | 255 | $4,037 |
| Potassium Citrate ErPotassium Citrate | 17 | $3,575 |
| Tolterodine Tartrate ErTolterodine Tartrate | 21 | $3,373 |
| Finasteride | 110 | $1,476 |
| Dutasteride | 35 | $1,273 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 44 | $900 |
| Cefdinir | 26 | $259 |
| Ciprofloxacin Hcl | 20 | $98 |
| Oxycodone Hcl | 19 | $48 |
| Levofloxacin | 19 | $26 |
| Amoxicillin | 12 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $215 | $55,78054 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $237 | $26,03919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 urology providers in Virginia.
Other urology in Suffolk
- Michael FabrizioVirginia Beach$1.5M
- Gregg EureVirginia Beach$1.4M
- Jessica DelongVirginia Beach$578K
- Robert GivenVirginia Beach$157K
- Michael WilliamsVirginia Beach$144K
- Nilay GandhiWoodbridge$138K
- Shawn MarhamatiWoodbridge$130K
- Jennifer Miles-ThomasVa Beach$101K
- Charles DanielRoanoke$94K
- David KageyRoanoke$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.